Volume 11, Issue 5 pp. 471-476

Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list

MATTHEW A ROBERTS

MATTHEW A ROBERTS

Departments of Nephrology and

Department of Medicine, University of Melbourne, and

Search for more papers by this author
NEIL MACMILLAN

NEIL MACMILLAN

Division of Laboratory Medicine, Austin Health,

Search for more papers by this author
DAVID L HARE

DAVID L HARE

Department of Medicine, University of Melbourne, and

Cardiology,

Search for more papers by this author
SUJIVA RATNAIKE

SUJIVA RATNAIKE

Department of Medicine, University of Melbourne, and

Division of Laboratory Medicine, Austin Health,

Search for more papers by this author
KEN SIKARIS

KEN SIKARIS

Melbourne Pathology Service, Melbourne, Victoria, Australia

Search for more papers by this author
MARGARET B FRAENKEL

MARGARET B FRAENKEL

Departments of Nephrology and

Search for more papers by this author
FRANCESCO L IERINO

Corresponding Author

FRANCESCO L IERINO

Departments of Nephrology and

Department of Medicine, University of Melbourne, and

Associate Professor Francesco L Ierino, Department of Nephrology, Austin Health, PO Box 5555, Heidelberg, Vic. 3084, Australia. Email: [email protected]Search for more papers by this author
First published: 29 September 2006
Citations: 13

SUMMARY:

Aims:  Cardiac troponin levels predict mortality and cardiovascular events in asymptomatic patients receiving dialysis and may be a useful clinical tool to stratify high-risk asymptomatic individuals.

Methods:  The present study examined levels of troponins I (cTnI) and T (cTnT) in patients with chronic renal impairment, patients receiving dialysis and renal transplant recipients. Patients receiving dialysis on the renal transplant waiting list were compared with those excluded from the list based on medical criteria. Median levels were compared using the Kruskal–Wallis test and proportions compared by chi-squared.

Results:  Median troponin levels were higher in patients on dialysis than transplant recipients. Comparing patients receiving dialysis not listed compared with those listed for renal transplant, median cTnI levels were significantly higher (0.03 versus 0.02 µg/L, P < 0.01) whereas median cTnT levels were not. Patients listed for transplantation were younger, had less clinical cardiovascular disease and lower C-reactive protein than those awaiting renal transplantation. The proportion of patients with elevated cTnT was not substantially different between patients awaiting renal transplantation (38%) and those excluded (52%). Levels of cTnI and cTnT were inversely related to renal function in predialysis and transplant patients, but were not related to time on dialysis for those receiving dialysis therapy.

Conclusion:  As patients awaiting renal transplantation are clinically screened for cardiovascular disease but have frequently elevated cardiac troponin levels, troponin may be a useful clinical tool to identify high-risk asymptomatic patients on dialysis prior to renal transplantation. The influence of renal function on the interpretation of cardiac troponin and risk prediction requires further evaluation.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.